Poet Technologies shares could reach $25 by 2027, a 200% gain from the current $8.33, according to an internal base case that targets $22.23 with moderate confidence. The stock has fallen 38.5% over the past month amid class action lawsuits alleging misrepresentation of Passive Foreign Investment Company status and a confidentiality breach by CFO Thomas Mika, alongside a $400 million dilutive offering and the CEO's retirement. The bull case hinges on the Malaysia facility ramping high-volume 800G production on schedule in the third quarter of 2026 and Lumilens converting its $50 million initial order into recurring revenue. The lone Wall Street analyst covering the stock has a 12-month consensus target of $17.50. Risks include further dilution or a customer qualification miss that could derail the ramp.
POET Technologies IncMalaysia facility ramp for 800G production and Lumilens order conversion could drive revenue
NVIDIA CorporationLumilens' $50 million initial order with POET could become recurring revenue